Neuren Pharmaceuticals Limited (NEU.AX)
Develops drugs to treat rare neurological disorders like Rett syndrome and Fragile X syndrome.
17.13+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+1.2%
The outlook
Neuren Pharmaceuticals trades at $17.13 with strong analyst backing—the consensus leans bullish, and the average price target sits roughly 41% above current levels. The stock sits midway through its 52-week range and trades above both its 50- and 200-day moving averages, suggesting steady upward positioning. At a trailing P/E of 74.5, the stock commands a premium valuation.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 6 analysts
Price trendAbove its 50- & 200-day averages
52-week range51% of the way from its 52-week low to high
Price targetAvg target +41% vs current price
Analyst price target
~12-month · 6 analysts24.13average target+40.8% vs now
Now 17.13
Low 19.10High 28.80
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.17B
52-wk high
22.99
52-wk low
11.00
50-day avg
14.99
200-day avg
15.65
Trailing P/E
74.5